Efficacy and safety of 5-aminolevulinic acid in adult-onset Still's disease : A preclinical study in mice and a pilot study in humans
Copyright © 2023. Published by Elsevier Inc..
The study aimed to investigate the therapeutic effects of 5-aminolevulinic acid/sodium ferrous citrate (5-ALA/SFC) on adult-onset Still's disease (AOSD), specifically focusing on arthritis and macrophage activation syndrome (MAS). We used mouse models to assess the impact of 5-ALA/SFC on collagen-induced arthritis (CIA) and MAS induced by synthetic oligonucleotides containing CpG motifs (CpG-S-ODN). Additionally, we conducted a pilot study with AOSD patients receiving prednisolone (PSL) treatment and 5-ALA/SFC administration to evaluate its efficacy and safety. The 5-ALA/SFC group exhibited significantly lower joint scores in CIA mice. In CpG-S-ODN-treated mice, 5-ALA/SFC administration led to reduced hemophagocytosis and splenomegaly. The anti-inflammatory properties of 5-ALA/SFC were attributed to the suppression of CCL4 and CXCL10 production in monocytes and the induction of M2 macrophages. AOSD patients treated with 5-ALA/SFC demonstrated successful PSL tapering without adverse events. Collectively, the administration of 5-ALA/SFC showed promising potential in ameliorating arthritis and MAS in AOSD patients.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:257 |
|---|---|
| Enthalten in: |
Clinical immunology (Orlando, Fla.) - 257(2023) vom: 25. Dez., Seite 109846 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Koga, Tomohiro [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 16.12.2023 Date Revised 10.04.2024 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.clim.2023.109846 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM364982497 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM364982497 | ||
| 003 | DE-627 | ||
| 005 | 20240410232313.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.clim.2023.109846 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1371.xml |
| 035 | |a (DE-627)NLM364982497 | ||
| 035 | |a (NLM)38007033 | ||
| 035 | |a (PII)S1521-6616(23)00610-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Koga, Tomohiro |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Efficacy and safety of 5-aminolevulinic acid in adult-onset Still's disease |b A preclinical study in mice and a pilot study in humans |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 16.12.2023 | ||
| 500 | |a Date Revised 10.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2023. Published by Elsevier Inc. | ||
| 520 | |a The study aimed to investigate the therapeutic effects of 5-aminolevulinic acid/sodium ferrous citrate (5-ALA/SFC) on adult-onset Still's disease (AOSD), specifically focusing on arthritis and macrophage activation syndrome (MAS). We used mouse models to assess the impact of 5-ALA/SFC on collagen-induced arthritis (CIA) and MAS induced by synthetic oligonucleotides containing CpG motifs (CpG-S-ODN). Additionally, we conducted a pilot study with AOSD patients receiving prednisolone (PSL) treatment and 5-ALA/SFC administration to evaluate its efficacy and safety. The 5-ALA/SFC group exhibited significantly lower joint scores in CIA mice. In CpG-S-ODN-treated mice, 5-ALA/SFC administration led to reduced hemophagocytosis and splenomegaly. The anti-inflammatory properties of 5-ALA/SFC were attributed to the suppression of CCL4 and CXCL10 production in monocytes and the induction of M2 macrophages. AOSD patients treated with 5-ALA/SFC demonstrated successful PSL tapering without adverse events. Collectively, the administration of 5-ALA/SFC showed promising potential in ameliorating arthritis and MAS in AOSD patients | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a 5-aminolevulinic acid/sodium ferrous citrate | |
| 650 | 4 | |a Adult-onset Still's disease | |
| 650 | 4 | |a Collagen-induced arthritis | |
| 650 | 4 | |a Macrophage activation syndrome | |
| 650 | 7 | |a Aminolevulinic Acid |2 NLM | |
| 650 | 7 | |a 88755TAZ87 |2 NLM | |
| 700 | 1 | |a Sumiyoshi, Remi |e verfasserin |4 aut | |
| 700 | 1 | |a Tsuji, Yoshika |e verfasserin |4 aut | |
| 700 | 1 | |a Kodama, Ken |e verfasserin |4 aut | |
| 700 | 1 | |a Endo, Yushiro |e verfasserin |4 aut | |
| 700 | 1 | |a Furukawa, Kaori |e verfasserin |4 aut | |
| 700 | 1 | |a Kawakami, Atsushi |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Clinical immunology (Orlando, Fla.) |d 1999 |g 257(2023) vom: 25. Dez., Seite 109846 |w (DE-627)NLM098196855 |x 1521-7035 |7 nnns |
| 773 | 1 | 8 | |g volume:257 |g year:2023 |g day:25 |g month:12 |g pages:109846 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.clim.2023.109846 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 257 |j 2023 |b 25 |c 12 |h 109846 | ||